Estimating leukemia-free survival after allografting for chronic myeloid leukemia: A new method that takes into account patients who relapse and are restored to complete remission

Blood

Volumn 96, Issue 1, 2000, Pages 86-90

  Craddock, Charles ^b   Szydlo, Richard M ^b   Klein, John P ^b   Dazzi, Francesco ^b   Olavarria, Eduardo ^b   Van Rhee, Frits ^b   Pocock, Christopher ^b   Cwynarski, Kate ^b   Apperley, Jane F ^b   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; METHOTREXATE; RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0034235910     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.86.013k54_86_90     Document Type: Article

References (33)

1. Clift R, Appelbaum F, Thomas E, et al. Treatment of chronic myeloid leukemia by marrow transplantation. Blood. 1993;82:1954.
2. Marks D, Hughes T, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992;81: 383.
3. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. Ann Intern Med. 1993;119:207.
4. Atkinson K, Downs K, Dodds A, Concannon A, Milliken S. Five year leukemia-free survival of 72% and 77% for early stage of acute and chronic myeloid leukemia treated by HLA-identical sibling bone marrow transplantation. Aust N Z J Med. 1996;26:54.
5. Hansen J, Gooley T, Martin P, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962.
6. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion reduces the incidence of graft-versus-host disease but increases the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53.
7. Goldman J, Gale R, Horowitz M, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806.
8. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120.
9. Higano C, Chielens D, Raskind W, et al. Use of alpha-2-interferon to treat cytogenetic relapse of chronic myeloid leukemia after transplantation. Blood. 1997;90:2549.
10. Radich J, Sanders J, Buckner C, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304.
11. Arcese W, Goldman JM, D'Arcangelo E, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood. 1993;82:3211.
12. Kolb HJ, Mittermuller J, Clemm CH, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462.
13. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse following allogeneic bone marrow transplantation [letter]. Blood. 1992;79:1379.
14. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310.
15. Porter DL, Roth MS, McGarigle G, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med. 1994;330:100.
16. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood. 1995;86:2041.
17. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433.
18. Porter DL, Collins RH, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5:253.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547.
20. Clift RA, Goldman JM, Gratwohl A, Horowitz MM. Proposals for standardized reporting of bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1989;4:445.
21. Klein JP, Szydlo RM, Craddock C, Goldman JM. Estimation of current leukemia free survival following donor lymphocyte infusion therapy for patients with leukemia who relapse after allografting: application of a multistate model. Statistics in Medicine. In press.
22. Speck B, Bortin M, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myeloid leukaemia. Lancet. 1984;1:665.
23. Spencer A, Szydlo R, Brookes P, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class II identity between donor and recipient. Blood. 1995;86:3590.
24. Cross N, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia after bone marrow transplantation. Blood. 1993;82:1929.
25. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leukocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99: 945.
26. Dazzi F, Szydlo RM, Craddock C, et al. A comparison of single dose and escalating dose regimens of donor lymphocyte infusion for patients who relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67.
27. Craddock C, Szydlo R, Olavarria E, et al. Leukemia free survival after allogeneic transplantation for chronic myeloid leukemia: effect of reclassifying responders to donor lymphocyte infusion as currently free of leukemia [abstract]. Blood. 1997; 10(suppl 1, part 2):378b.
28. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83:3377.
29. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337.
30. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia effect from graft-versus-host disease. Blood. 1995;86:1261.
31. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell depleted and non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561.
32. Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Keever-Taylor CA. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood. 1999;94:434.
33. Slavin S, Nagler A, Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756.